Who Invented CJC-1295? ConjuChem's Albumin Idea

The researchers who invented CJC-1295 worked at ConjuChem in Montreal. Lucie Jetté, Roger Léger, Dominique Bridon and colleagues described it in a 2005 paper. They were tackling a practical problem: how to make a short-lived hormone signal stay in the blood longer.

Their solution attached the signal to a protein already circulating in blood. That engineering idea explains both the original molecule and much of the confusion around its name today.

Who invented CJC-1295 at ConjuChem?

ConjuChem's research team developed CJC-1295 as a longer-lasting, modified version of the first 29 amino acids of growth-hormone-releasing hormone, or GHRH. That's the body's message telling the pituitary, a small gland beneath the brain, to release growth hormone.

Peptides are short chains of amino acids, the building blocks of proteins. Many disappear quickly because enzymes break them apart and the kidneys remove them. ConjuChem wanted to extend that exposure without stopping the peptide from sending its message.

The team's 2005 paper in Endocrinology tested three candidates in rat cells and rats. CJC-1295 was selected for further study.

What the name and drug affinity complex mean

CJC-1295 was the compound identifier used in that paper. DAC stands for drug affinity complex, a chemical attachment that bonds the peptide to albumin, a plentiful blood protein. Albumin acts as a carrier, keeping the attached signal around longer.

The original design changed four amino acids: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. These changes addressed breakdown, chemical stability and activity. An extra lysine, another amino acid, carried the albumin-binding attachment at the chain's end.

There was an earlier branch of this work. Kim and colleagues' 2003 Diabetes paper described CJC-1131, an albumin-binding version of GLP-1, a gut hormone involved in blood-sugar control. Tiessen and colleagues later reported human CJC-1131 studies in 2008.

Albumin binding also appears in the history of semaglutide, though its attachment uses different chemistry. Sharing a carrier idea doesn't make the drugs interchangeable.

Today's CJC-1295/ipamorelin pairing adds ipamorelin, a separate peptide that prompts growth hormone release. It wasn't part of ConjuChem's original molecule.

When the first human studies appeared

Sam Teichman and colleagues' first human trials appeared online December 13, 2005, before their March 2006 journal issue; our CJC-1295 clinical-trial guide explains the results.

A second paper asked whether a lasting signal would flatten growth hormone's normal rhythm. Madalina Ionescu and Lawrence Frohman, at the University of Illinois at Chicago, reported in 2006 that overnight bursts of hormone release persisted. Levels between bursts increased.

That distinction matters: a drug can remain in the blood while the gland still releases hormone in pulses. Neither paper established a benefit for sleep, muscle strength or recovery. Both studied the albumin-binding molecule alone, not a combination with ipamorelin.

Why was CJC-1295 development stopped?

ConjuChem moved into a phase 2 trial, an early patient study, for excess abdominal fat associated with HIV. That was a specific medical question, separate from today's broader wellness claims.

The company announced a trial pause on July 14, 2006, after a participant died at a study site in Argentina. It stopped further dosing while investigating.

Its August 8 investigation announcement said the participant felt chest discomfort about two hours after receiving an 11th weekly dose on July 13; an ECG confirmed a heart attack, and the participant died about an hour later. The fuller company statement, preserved in an archived copy, said the attending physician's most likely explanation was previously silent coronary artery disease. That means disease in the arteries supplying the heart.

This was the company's account, not proof that CJC-1295 caused the death or proof that it was unrelated. The trial registry records termination without posted results. A stopped study cannot establish the treatment benefit it set out to test.

How the name reached the gray market

The name survived the clinical program. In a 2010 Drug Testing and Analysis paper, Norwegian scientists described an unknown preparation submitted for analysis in 2009. They identified a 29-amino-acid peptide consistent with material marketed as CJC-1295.

FDA's December 2024 briefing document notes that the Norwegian authors found no DAC in this preparation and calls it the first reference to CJC-1295 without DAC in the literature. The molecule commonly called CJC-1295 without DAC, or modified GRF 1-29, differs from the albumin-binding original. Its name cannot carry over the original's duration findings.

As of October 29, 2026, the day this article was written, an August 11, 2026 review in The American Journal of Sports Medicine examined six peptides, including CJC-1295. It found that current human trials did not substantiate the claimed muscle-and-joint recovery or performance benefits.

Where CJC-1295 stands today

As of October 29, 2026, the day this article was written, HHS, the U.S. health department, has filed notice of a draft peptide-compounding policy on October 28. CJC-1295 is absent from its six-peptide Appendix A; the HHS policy explainer covers the conditions.

CJC-1295 is not FDA-approved. A compounded medication, prepared for an individual prescription, is different from an FDA-approved product. FDA's safety page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn. It says compounded CJC-1295 may pose a risk of immunogenicity (the body mounting an immune reaction to the peptide) and may have impurity and characterization problems, that FDA has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction (blood vessels widening throughout the body), and that available clinical data are limited. The FDA review history explains that record. A licensed provider may still prescribe — that decision is between you and your doctor.

As of October 29, 2026, the day this article was written, the World Anti-Doping Agency has published its 2027 list. Released September 21, 2026, it names CJC-1295 under section S2. It prohibits it during and outside competition; that edition takes effect January 1, 2027.

Where sermorelin fits in the family tree

GRF is another name for GHRH, the body's hormone-release message. GRF(1-29) means its first 29 building blocks, the fragment ConjuChem started with. Sermorelin copies that fragment without CJC-1295's four substitutions or albumin-binding extension.

Its history differs. Today's compounded sermorelin is different from an FDA-approved sermorelin product once marketed as Geref and since discontinued. The compounded formulation offered here is not FDA-approved. FDA's 2013 notice determined that Geref was not withdrawn for safety or effectiveness reasons.

That makes sermorelin a related prescription discussion, with its own evidence, rather than another name for CJC-1295.

What the history means for a prescription

CJC-1295 on its own is coming soon to Promise; the formulation Promise will offer is not FDA-approved. The CJC-1295/ipamorelin pair is the offered product, and its compounded formulation is not FDA-approved.

At Promise, a licensed provider reviews every request and not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares and dispenses the medication. The prescriber sets the treatment and follow-up plan.

The useful question is which exact molecule is being considered and which evidence applies to it. A company name, a familiar code or an older hormone study cannot answer that for an individual prescription.